Bessemer Group’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-182,357
Closed -$8.05M 2629
2025
Q1
$8.05M Hold
182,357
0.01% 315
2024
Q4
$6.59M Sell
182,357
-65
-0% -$2.27K 0.01% 366
2024
Q3
$5.84M Sell
182,422
-105
-0.1% -$3.92K 0.01% 393
2024
Q2
$6.88M Buy
182,527
+170
+0.1% +$7.16K 0.01% 334
2024
Q1
$8.98M Sell
182,357
-58,980
-24% -$2.73M 0.02% 321
2023
Q4
$8.81M Hold
241,337
0.02% 309
2023
Q3
$5.58M Hold
241,337
0.01% 339
2023
Q2
$6.33M Hold
241,337
0.01% 320
2023
Q1
$6.21M Hold
241,337
0.01% 309
2022
Q4
$6.28M Hold
241,337
0.02% 303
2022
Q3
$6.88M Hold
241,337
0.02% 287
2022
Q2
$5.94M Hold
241,337
0.01% 289
2022
Q1
$13.6M Hold
241,337
0.03% 204
2021
Q4
$15M Hold
241,337
0.03% 196
2021
Q3
$15.3M Hold
241,337
0.03% 207
2021
Q2
$19.9M Sell
241,337
-45,000
-16% -$3.42M 0.04% 205
2021
Q1
$21.1M Sell
286,337
-47,000
-14% -$3.68M 0.05% 203
2020
Q4
$24.2M Hold
333,337
0.06% 187
2020
Q3
$15.9M Sell
333,337
-87,945
-21% -$3.75M 0.05% 186
2020
Q2
$17.7M Hold
421,282
0.06% 188
2020
Q1
$11.4M Buy
+421,282
New +$13.7M 0.05% 224

Other funds holding SWTX

Bessemer Group's SWTX Position: Q2 2025 in Review

Bessemer Group sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 182,357 shares — an estimated $8.05M sold.

Bessemer Group first reported a position in SWTX in Q1 2020 and held it in 21 quarters. The position peaked at $24.2M in Q4 2020. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Bessemer Group reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bessemer Group sold 182,357 SpringWorks Therapeutics shares in Q2 2025, an estimated $8.05M.
  • Bessemer Group first reported a position in SpringWorks Therapeutics in Q1 2020 and held it in 21 quarters.
  • Bessemer Group's SpringWorks Therapeutics position peaked at $24.2M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Bessemer Group's 13F filing for Q2 2025, filed 1 Aug 2025.